D. Christoulas

Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid

Meletios Α. Dimopoulos, Efstathios Kastritis, Christina Bamia et al. · Annals of Oncology · 2008 · 437 citations · Full text

Medicine, Oncology, Bone Metabolism +9

Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG)

Efstathios Kastritis, Konstantinos Zervas, Argiris Symeonidis et al. · Leukemia · 2009 · 187 citations

Medicine, Hematology, Oncology +17

Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies

Meletios Α. Dimopoulos, Efstathios Kastritis, D. Christoulas et al. · Leukemia · 2010 · 118 citations

Medicine, Hematology, Pharmacotherapy +17

The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis

Evangelos Terpos, Efstathios Kastritis, D Heath et al. · Leukemia · 2008 · 115 citations

Medicine, Hematology, Pharmacology +17

Circulating activin-A is elevated in patients with advanced multiple myeloma and correlates with extensive bone involvement and inferior survival; no alterations post-lenalidomide and dexamethasone therapy

Evangelos Terpos, Efstathios Kastritis, D. Christoulas et al. · Annals of Oncology · 2012 · 111 citations · Full text

Medicine, Hematology, Oncology +16